SUO 2016: Clinical implications for prostate cancer screening and treatment of men with germline mutations in BRCA and other DNA repair genes - Session Highlights


San Antonio, Texas USA (UroToday.com) Heather Cheng, University of Washington, discussed BRCA and other DNA-repair genes in prostate cancer. All men with metastatic prostate cancer should be offered germline genetic testing.

SUO 2016: Germline susceptibility for bladder cancer- Session Highlights


San Antonio, Texas USA (UroToday.com) Andrew K. Kadar, University of California San Diego, further discussed germline susceptibility for bladder cancer diagnosis and treatment.

SUO 2016: Inherited DNA-repair gene mutations in men with metastatic prostate cancer - Session Highlights


San Antonio, Texas USA (UroToday.com) Peter Nelson, University of Washington, discussed DNA-repair genetic variants in men with metastatic prostate cancer. Only 1-2% of the population have defects in DNA-repair genes, however, the prevalence is more common among metastatic prostate cancer patients with up to 8% having germline aberrations.

SUO 2016: Prostate SNPs: Clinical applicability for screening and chemoprevention - Session Highlights


San Antonio, Texas USA (UroToday.com) Andrew K. Kader, University of California San Diego, discussed genetic variants in prostate cancer and potential role in screening and prevention. Recent stage migration has resulted in a shift of identifying indolent prostate cancer with concern regarding over diagnosis, over treatment, morbidity and increased costs associated with diagnosis and treatment of prostate cancer.

SUO 2016: Germline Implications of Somatic Profiling - Session Highlights


San Antonio, Texas USA (UroToday.com) Mark E. Robson, Memorial Sloan Kettering Cancer Center (MSKCC), discussed somatic profiling in urologic oncology. Multigene panel testing screens for a number of genes at the same time with various panels for particular malignancies. Unfortunately, this is inefficient and costly.